Anaplastic glioma: current treatment and management.
Anaplastic glioma (AG) is divided into three morphology-based groups (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma) as well as three molecular groups (glioma-CpG island methylation phenotype [G-CIMP] negative, G-CIMP positive non-1p19q codeleted tumors and G-CIMP positive codeleted tumors). The RTOG 9402 and EORTC 26951 trials established radiotherapy plus (procarbazine, lomustine, vincristine) chemotherapy as the standard of care in 1p/19q codeleted AG. Uni- or non-codeleted AG are currently best treated with radiotherapy only or alkylator-based chemotherapy only as determined by the NOA-04 trial. Maturation of NOA-04 and results of the currently accruing studies, CODEL (for codeleted AG) and CATNON (for uni or non-codeleted AG), will likely refine current up-front treatment recommendations for AG.
Department of Neuro-oncology, Roger Salengro Hospital, University Hospital, Lille, France.
Emilie
E
Le Rhun
Sophie
S
Taillibert
Marc C
MC
Chamberlain
D001932:Brain Neoplasms / Q000145:classification / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D019468:Disease Management; D005910:Glioma / Q000145:classification / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics; D009154:Mutation / Q000235:genetics
D007521:Isocitrate Dehydrogenase
1p/19q codeletion; ATRX; IDH1; MGMT promoter methylation; anaplastic glioma; bevacizumab; chemotherapy; molecular biomarkers; nitrosourea; radiotherapy; temozolomide